Shengmai Yin(SMY)is a Chinese herbal decoction that effectively alleviates the side effects of radiotherapy in various cancers and helps achieve radiotherapy’s clinical efficacy.In this study,we explored the interact...Shengmai Yin(SMY)is a Chinese herbal decoction that effectively alleviates the side effects of radiotherapy in various cancers and helps achieve radiotherapy’s clinical efficacy.In this study,we explored the interaction mechanism among SMY,DNA methylation,and nasopharyngeal carcinoma(NPC).We identified differences in DNA methylation levels in NPC CNE-2 cells and its radioresistant cells(CNE-2R)using the methylated DNA immunoprecipitation array and found that CNE-2R cells showed genomewide changes in methylation status towards a state of hypomethylation.SMY may restore its original DNA methylation status,and thus,enhance radiosensitivity.Furthermore,we confirmed that the differential gene Tenascin-C(TNC)was overexpressed in CNE-2R cells and that SMY downregulated TNC expression.This downregulation of TNC inhibited NPC cell radiation resistance,migration,and invasion.Furthermore,we found that TNC was hypomethylated in CNE-2R cells and partially restored to a hypermethylated state after SMY intervention.DNA methyltransferases 3 a may be the key protein in DNA methylation of TNC.展开更多
目的:观察黄芪生脉饮联合盐酸米多君治疗血液透析相关性低血压的疗效。方法:收集2012年12月-2017年12月原武警北京市总队第三医院门诊透析治疗的尿毒症患者45例,入选患者透析时间≥1年,血液透析治疗中收缩压下降到90 mm Hg(1 mm Hg≈0.1...目的:观察黄芪生脉饮联合盐酸米多君治疗血液透析相关性低血压的疗效。方法:收集2012年12月-2017年12月原武警北京市总队第三医院门诊透析治疗的尿毒症患者45例,入选患者透析时间≥1年,血液透析治疗中收缩压下降到90 mm Hg(1 mm Hg≈0.133 kPa)以下或平均动脉压较透析前下降30 mm Hg以上,并且伴有头晕、大汗、心慌、胸闷、腹痛、恶心、呕吐、视物模糊等症状,甚至需要紧急处理或终止治疗。使用随机对照法将观察对象分为两组,观察组25例,对照组20例,两组性别、年龄、透析龄、原发病等指标的差异没有统计学意义(P>0.05)。对照组给予常规血液透析和治疗,观察组在相同的血液透析治疗的基础上给予黄芪生脉饮10 mL,口服,每日3次;盐酸米多君片5 mg,透析前1小时口服。治疗3个月后记录两组的血压和临床症状,并进行统计分析。结果:经过3个月治疗,观察组的临床症状如头晕、恶心、呕吐、心慌、胸闷等好转,有效率71.13%(537/755)、好转率24.24%(183/755)、总有效率95.36%(720/755)均高于对照组,差异有统计学意义(P<0.05)。观察组和对照组血压比较,在透析前两组收缩压和舒张压的差异没有统计学意义(P>0.05);透析中和透析结束后比较,观察组的收缩压和舒张压均高于对照组。并且,在治疗过程中血压维持稳定(P<0.05)。结论:黄芪生脉饮联合盐酸米多君可以有效治疗透析相关性低血压,维持正常血液透析治疗,提高患者的生存率和生存质量,值得在临床应用推广。展开更多
OBJECTIVE:To evaluate the efficacy and safety of Shengmai Yin(生脉饮,SMY)on visual analogue scale(VAS)for cardiopulmonary symptoms in coronavirus disease 2019(COVID-19)convalescent patients.METHODS:In this randomized,...OBJECTIVE:To evaluate the efficacy and safety of Shengmai Yin(生脉饮,SMY)on visual analogue scale(VAS)for cardiopulmonary symptoms in coronavirus disease 2019(COVID-19)convalescent patients.METHODS:In this randomized,double blind and multicenter controlled trial,a total of 200 COVID-19 convalescent patients who with cardiopulmonary symptoms were enrolled from three medical centers in Hubei,China.These patients were randomized divided into trial group and the control group,100 patients in each one,SMY and its placebo were applied to respectively,for two weeks.VAS of clinical symptoms included shortness of breath,hidrosis,chest distress,palpitation,and dry cough was performed at 0,1,2 weeks.Decrease in VAS of 30%or more was defined as effective,and a reduction in VAS of 0 was defined as curative.RESULTS:A total of 192 completed the study.The VAS of TCM symptoms showed there was no difference in baseline between the two groups.The VAS in both groups was down-regulated,and there was no significant difference in VAS and cure rates at the first and second week between the two groups.There was no significant difference in breath,hidrosis,palpitation,and dry cough between the two groups but SMY treatment for two weeks has remarkable therapeutic effects in chest distress than placebo.CONCLUSIONS:SMY could effectively ameliorate the symptoms of chest distress,and improve the quality of life of the COVID-19 convalescent patients.展开更多
基金supported by the National Natural Science Foundation of China(Grant Nos.:81673718 and 82074132)the Technology Project of Guangdong Province(Grant No.:2016A020226034)。
文摘Shengmai Yin(SMY)is a Chinese herbal decoction that effectively alleviates the side effects of radiotherapy in various cancers and helps achieve radiotherapy’s clinical efficacy.In this study,we explored the interaction mechanism among SMY,DNA methylation,and nasopharyngeal carcinoma(NPC).We identified differences in DNA methylation levels in NPC CNE-2 cells and its radioresistant cells(CNE-2R)using the methylated DNA immunoprecipitation array and found that CNE-2R cells showed genomewide changes in methylation status towards a state of hypomethylation.SMY may restore its original DNA methylation status,and thus,enhance radiosensitivity.Furthermore,we confirmed that the differential gene Tenascin-C(TNC)was overexpressed in CNE-2R cells and that SMY downregulated TNC expression.This downregulation of TNC inhibited NPC cell radiation resistance,migration,and invasion.Furthermore,we found that TNC was hypomethylated in CNE-2R cells and partially restored to a hypermethylated state after SMY intervention.DNA methyltransferases 3 a may be the key protein in DNA methylation of TNC.
文摘目的:观察黄芪生脉饮联合盐酸米多君治疗血液透析相关性低血压的疗效。方法:收集2012年12月-2017年12月原武警北京市总队第三医院门诊透析治疗的尿毒症患者45例,入选患者透析时间≥1年,血液透析治疗中收缩压下降到90 mm Hg(1 mm Hg≈0.133 kPa)以下或平均动脉压较透析前下降30 mm Hg以上,并且伴有头晕、大汗、心慌、胸闷、腹痛、恶心、呕吐、视物模糊等症状,甚至需要紧急处理或终止治疗。使用随机对照法将观察对象分为两组,观察组25例,对照组20例,两组性别、年龄、透析龄、原发病等指标的差异没有统计学意义(P>0.05)。对照组给予常规血液透析和治疗,观察组在相同的血液透析治疗的基础上给予黄芪生脉饮10 mL,口服,每日3次;盐酸米多君片5 mg,透析前1小时口服。治疗3个月后记录两组的血压和临床症状,并进行统计分析。结果:经过3个月治疗,观察组的临床症状如头晕、恶心、呕吐、心慌、胸闷等好转,有效率71.13%(537/755)、好转率24.24%(183/755)、总有效率95.36%(720/755)均高于对照组,差异有统计学意义(P<0.05)。观察组和对照组血压比较,在透析前两组收缩压和舒张压的差异没有统计学意义(P>0.05);透析中和透析结束后比较,观察组的收缩压和舒张压均高于对照组。并且,在治疗过程中血压维持稳定(P<0.05)。结论:黄芪生脉饮联合盐酸米多君可以有效治疗透析相关性低血压,维持正常血液透析治疗,提高患者的生存率和生存质量,值得在临床应用推广。
基金Supported by Randomized,Double-blind,Placebo-controlled,Multicenter Clinical Study to Improve Symptoms Associated with Pulmonary Heart Function during Recovery from COVID-19(II)(No.2020ZYLCYJ08-4)。
文摘OBJECTIVE:To evaluate the efficacy and safety of Shengmai Yin(生脉饮,SMY)on visual analogue scale(VAS)for cardiopulmonary symptoms in coronavirus disease 2019(COVID-19)convalescent patients.METHODS:In this randomized,double blind and multicenter controlled trial,a total of 200 COVID-19 convalescent patients who with cardiopulmonary symptoms were enrolled from three medical centers in Hubei,China.These patients were randomized divided into trial group and the control group,100 patients in each one,SMY and its placebo were applied to respectively,for two weeks.VAS of clinical symptoms included shortness of breath,hidrosis,chest distress,palpitation,and dry cough was performed at 0,1,2 weeks.Decrease in VAS of 30%or more was defined as effective,and a reduction in VAS of 0 was defined as curative.RESULTS:A total of 192 completed the study.The VAS of TCM symptoms showed there was no difference in baseline between the two groups.The VAS in both groups was down-regulated,and there was no significant difference in VAS and cure rates at the first and second week between the two groups.There was no significant difference in breath,hidrosis,palpitation,and dry cough between the two groups but SMY treatment for two weeks has remarkable therapeutic effects in chest distress than placebo.CONCLUSIONS:SMY could effectively ameliorate the symptoms of chest distress,and improve the quality of life of the COVID-19 convalescent patients.
